×
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80

Reneo Pharmaceuticals Stock Forecast, Price & News

$2.83
-0.08 (-2.75%)
(As of 07/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.73
$3.08
50-Day Range
$1.96
$2.91
52-Week Range
$1.92
$11.40
Volume
75,993 shs
Average Volume
122,577 shs
Market Capitalization
$69.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.80

Reneo Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
847.0% Upside
$26.80 Price Target
Short Interest
Healthy
3.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.47) to ($2.50) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.17 out of 5 stars

Medical Sector

300th out of 1,433 stocks

Pharmaceutical Preparations Industry

135th out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive RPHM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Reneo Pharmaceuticals

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

RPHM Stock News Headlines

Is the US Military Secretly Under Chinese Control?
Alarmingly, the answer may be "yes". Communist China now controls 80% of the lithium that powers most US military vehicles and equipment. The threat level is so high that the White House recently declared a state of emergency on lithium...
Is the US Military Secretly Under Chinese Control?
Alarmingly, the answer may be "yes". Communist China now controls 80% of the lithium that powers most US military vehicles and equipment. The threat level is so high that the White House recently declared a state of emergency on lithium...
Reneo Pharmaceuticals Inc.
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RPHM
Fax
N/A
Employees
24
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
7/07/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$26.80
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+847.0%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
5 Analysts

Profitability

Net Income
$-39,770,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.03 per share

Miscellaneous

Free Float
20,692,000
Market Cap
$69.22 million
Optionable
Not Optionable
Beta
0.56














Reneo Pharmaceuticals Frequently Asked Questions

Should I buy or sell Reneo Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reneo Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Reneo Pharmaceuticals stock.
View analyst ratings for Reneo Pharmaceuticals
or view top-rated stocks.

What is Reneo Pharmaceuticals' stock price forecast for 2022?

5 Wall Street research analysts have issued 12 month target prices for Reneo Pharmaceuticals' shares. Their RPHM stock forecasts range from $15.00 to $45.00. On average, they predict Reneo Pharmaceuticals' share price to reach $26.80 in the next twelve months. This suggests a possible upside of 847.0% from the stock's current price.
View analysts' price targets for Reneo Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Reneo Pharmaceuticals' stock price performed in 2022?

Reneo Pharmaceuticals' stock was trading at $8.55 on January 1st, 2022. Since then, RPHM shares have decreased by 66.9% and is now trading at $2.83.
View the best growth stocks for 2022 here
.

When is Reneo Pharmaceuticals' next earnings date?

Reneo Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Reneo Pharmaceuticals
.

How were Reneo Pharmaceuticals' earnings last quarter?

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) posted its earnings results on Tuesday, May, 10th. The company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.01.
View Reneo Pharmaceuticals' earnings history
.

Who are Reneo Pharmaceuticals' key executives?

Reneo Pharmaceuticals' management team includes the following people:
  • Mr. Michael G. Grey, Founder & Exec. Chairman (Age 69)
  • Mr. Gregory J. Flesher, Pres, CEO & Director (Age 52, Pay $743.05k) (LinkedIn Profile)
  • Mr. Michael P. Cruse, Chief Operating Officer (Age 50, Pay $423.3k) (LinkedIn Profile)
  • Mr. Vineet R. Jindal, Consultant (Age 44, Pay $568.27k) (LinkedIn Profile)
  • Ms. Jennifer P. Lam, Principal Financial & Accounting Officer
  • Ms. Wendy S. Johnson M.B.A., Consultant (Age 70)
  • Dr. Alejandro Dorenbaum, Chief Medical Officer (Age 61)
  • Ms. Lynn Purkins Ph.D., Sr. VP of Clinical Operations
  • Ms. Ashley F. Hall J.D., Chief Devel. Officer (Age 50)

When did Reneo Pharmaceuticals IPO?

(RPHM) raised $101 million in an initial public offering on Friday, April 9th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

What is Reneo Pharmaceuticals' stock symbol?

Reneo Pharmaceuticals trades on the NASDAQ under the ticker symbol "RPHM."

How do I buy shares of Reneo Pharmaceuticals?

Shares of RPHM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reneo Pharmaceuticals' stock price today?

One share of RPHM stock can currently be purchased for approximately $2.83.

How much money does Reneo Pharmaceuticals make?

Reneo Pharmaceuticals (NASDAQ:RPHM) has a market capitalization of $69.22 million. The company earns $-39,770,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis.

How many employees does Reneo Pharmaceuticals have?

Reneo Pharmaceuticals employs 24 workers across the globe.

How can I contact Reneo Pharmaceuticals?

The official website for Reneo Pharmaceuticals is reneopharma.com. The company can be reached via phone at 858-283-0280 or via email at investors@reneopharma.com.

This page (NASDAQ:RPHM) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.